SCHEMBL9752099

SCHEMBL9752099

CC12CCC(C1)C(C)(C)C2(C)O

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 3/20 0.36
APOBEC3A P31941 2/20 0.36
APOBEC3G Q9HC16 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 3/20 0.32
SIGMAR1 Q99720 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 2/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
KMT2A Q03164 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30
RECQL P46063 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29365026 1.00 CTDSP1 (0.36) CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA
SCHEMBL30754386 1.00 CTDSP1 (0.36) CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA
SCHEMBL31338805 1.00 CTDSP1 (0.36) CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA
SCHEMBL16779993 1.00 CTDSP1 (0.36) CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA
SCHEMBL11810368 0.85 CTDSP1 (0.39) CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA
Methyl Alcohol SCHEMBL1155257 0.80 CTDSP1 (0.43) CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA
SCHEMBL1024401 0.79
SCHEMBL221719 0.74 CTDSP1 (0.37) CTDSP1APOBEC3AAPOBEC3GLMNASIGMAR1
SCHEMBL14867338 0.74 CTDSP1 (0.37) CTDSP1APOBEC3AAPOBEC3GLMNASIGMAR1
Acetic Acid SCHEMBL189531 0.73 CTDSP1 (0.38) CTDSP1APOBEC3AAPOBEC3GL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
JP-3024198-A None JP disclosed
EP-4519404-A1 METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN Firmenich SA (CH) 2025-03-12 EP disclosed
WO-2023247604-A1 METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN FIRMENICH SA (CH) 2023-12-28 WO disclosed
US-11802258-B2 Perfume precursor TAKASAGO INTERNATIONAL CORPORATION (JP) 2023-10-31 US disclosed
US-20210214644-A1 PERFUME PRECURSOR TAKASAGO INTERNATIONAL CORPORATION (JP) 2021-07-15 US disclosed
EP-3689849-A1 PERFUME PRECURSOR Takasago International Corporation (JP) 2020-08-05 EP disclosed
JP-H0324198-A PERFUME COMPOSITION AND BLEACHING AGENT COMPOSITION TAKASAGO INTERNATL CORP 1991-02-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802258-B2 Perfume precursor CYP2E1, ADH1A, CYP1A1 CTDSP1 551/4885APOBEC3A 4494/4885APOBEC3G 4658/4885
US-20210214644-A1 PERFUME PRECURSOR CYP2E1, ADH1A, CYP1A1 CTDSP1 551/4885APOBEC3A 4494/4885APOBEC3G 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.